-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $13.25
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $13.25
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $13.25, but opened at $11.94. Janux Therapeutics shares last traded at $13.34, with a volume of 174 shares traded.
Janux Therapeutics Trading Up 2.3 %
The firm has a market capitalization of $564.91 million, a price-to-earnings ratio of -9.05 and a beta of 1.69. The stock has a fifty day moving average of $13.34 and a 200-day moving average of $13.04.
Get Janux Therapeutics alerts:Janux Therapeutics (NASDAQ:JANX – Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04). The business had revenue of $2.37 million during the quarter. Janux Therapeutics had a negative return on equity of 15.10% and a negative net margin of 809.63%. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.74 earnings per share for the current fiscal year.
Institutional Trading of Janux Therapeutics
A number of institutional investors have recently bought and sold shares of JANX. Amalgamated Bank acquired a new stake in Janux Therapeutics during the first quarter valued at $28,000. Parkwood LLC boosted its position in Janux Therapeutics by 19.4% during the second quarter. Parkwood LLC now owns 33,750 shares of the company's stock valued at $34,000 after purchasing an additional 5,492 shares during the last quarter. American International Group Inc. lifted its position in shares of Janux Therapeutics by 25.3% in the first quarter. American International Group Inc. now owns 8,813 shares of the company's stock worth $126,000 after buying an additional 1,782 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Janux Therapeutics by 100.2% during the 1st quarter. MetLife Investment Management LLC now owns 10,614 shares of the company's stock worth $152,000 after acquiring an additional 5,312 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Janux Therapeutics by 63.0% during the 1st quarter. New York State Common Retirement Fund now owns 15,521 shares of the company's stock valued at $223,000 after acquiring an additional 6,000 shares during the last quarter. Institutional investors and hedge funds own 69.40% of the company's stock.Janux Therapeutics Company Profile
(Get Rating)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
See Also
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $13.25, but opened at $11.94. Janux Therapeutics shares last traded at $13.34, with a volume of 174 shares traded.
JANUX治療公司(納斯達克：JANX-GET評級)週二盤前下跌。該股此前收盤報13.25美元，開盤報11.94美元。Janux Treateutics的股票尾盤報13.34美元，成交量為174股。
Janux Therapeutics Trading Up 2.3 %
Janux治療公司股價上漲2.3%
The firm has a market capitalization of $564.91 million, a price-to-earnings ratio of -9.05 and a beta of 1.69. The stock has a fifty day moving average of $13.34 and a 200-day moving average of $13.04.
該公司的市值為5.6491億美元，市盈率為-9.05倍，貝塔係數為1.69。該股的50日移動均線切入位為13.34美元，200日移動均線切入位為13.04美元。
Janux Therapeutics (NASDAQ:JANX – Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04). The business had revenue of $2.37 million during the quarter. Janux Therapeutics had a negative return on equity of 15.10% and a negative net margin of 809.63%. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.74 earnings per share for the current fiscal year.
雅諾治療公司(納斯達克代碼：JANX-GET評級)上一次發佈財報是在8月9日星期二。該公司公佈了該季度每股收益(0.41美元)，低於普遍預期的(0.37美元)和(0.04美元)。該業務本季度的收入為237萬美元。雅諾治療公司的淨資產回報率為負15.10%，淨利潤率為負809.63%。股票研究分析師預測，Janux治療公司本財年的每股收益將達到1.74美元。
Institutional Trading of Janux Therapeutics
JANUX治療公司的機構交易
Janux Therapeutics Company Profile
Janux治療公司簡介
(Get Rating)
(獲取評級)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Janux治療公司是一家生物製藥公司，開發基於專有的腫瘤激活T細胞激活器(TRACTr)平臺技術的療法，用於治療癌症患者。該公司處於臨牀前或發現階段的主要候選TRACTr產品針對前列腺特異性膜抗原、表皮生長因子受體和滋養層細胞表面抗原2。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- 免費獲取StockNews.com關於Janux治療公司的研究報告(Janx)
- AMD股票是不是跌得太厲害了？
- 甲骨文的短期痛苦可能是你的長期收益
- Lucid看起來像是電動汽車的贏家
- 仍然愛着它：投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎？
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Janux治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Janux治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧